Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model - Wikidata - awgldk - TriplyDB

Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model

Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model

http://www.wikidata.org/entity/Q37733544

about

Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis Respiratory syncytial virus-induced acute and chronic airway disease is independent of genetic background: an experimental murine model.Hyperresponsiveness to inhaled but not intravenous methacholine during acute respiratory syncytial virus infection in mice Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies Interferon-gamma coordinates CCL3-mediated neutrophil recruitment in vivo.Genomewide association analysis of respiratory syncytial virus infection in mice.Effects of anti-g and anti-f antibodies on airway function after respiratory syncytial virus infection Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice Immune responses and disease enhancement during respiratory syncytial virus infection Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency.Combination therapy using monoclonal antibodies against respiratory syncytial virus (RSV) G glycoprotein protects from RSV disease in BALB/c mice.A broadly neutralizing human monoclonal antibody exhibits in vivo efficacy against both human metapneumovirus and respiratory syncytial virus.Major histocompatibility complex-dependent cytotoxic T lymphocyte repertoire and functional avidity contribute to strain-specific disease susceptibility after murine respiratory syncytial virus infection Prospects of antiviral and anti-inflammatory therapy for respiratory syncytial virus infection.Motavizumab, a neutralizing anti-Respiratory Syncytial Virus (Rsv) monoclonal antibody significantly modifies the local and systemic cytokine responses induced by Rsv in the mouse model Prevention and treatment of respiratory syncytial virus infection in infants: an update.Respiratory syncytial virus persistence in the lungs correlates with airway hyperreactivity in the mouse model.Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)Passive immunization of neonatal mice against Pneumocystis carinii f. sp. muris enhances control of infection without stimulating inflammation.Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants.A review of cost-effectiveness of palivizumab for respiratory syncytial virus.Risk of respiratory syncytial virus infection in preterm infants: reviewing the need for prevention.Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater In Vivo Protection than the Murine Precursor of Palivizumab.Antiviral effect of emodin from Rheum palmatum against coxsakievirus B5 and human respiratory syncytial virus in vitro.Respiratory syncytial virus pathophysiology and affect of palivizumab in special populations: cystic fibrosis and immunosuppression.Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection.Respiratory syncytial virus (RSV) RNA loads in peripheral blood correlates with disease severity in mice.Steroid resistance and concomitant respiratory infections: A challenging battle in pulmonary clinic.Intravenous palivizumab in respiratory syncytial virus infection after hematopoietic stem cell transplant in children.Pathogenesis of human metapneumovirus lung infection in BALB/c mice and cotton rats Novel Ranking System for Identifying Efficacious Anti-Influenza Virus PB2 Inhibitors.Contribution of Fcγ receptors to human respiratory syncytial virus pathogenesis and the impairment of T-cell activation by dendritic cells.Acute respiratory infection with mouse adenovirus type 1 Respiratory syncytial virus detection in cells and clinical samples by using three new monoclonal antibodies.Pericarditis mediated by respiratory syncytial virus in a hematopoietic stem cell transplant patient.

P2860

Q24194584-724A952B-7113-40E0-9462-770F9F8682FD Q24202211-68FBF811-A9D2-4F80-AA8E-4FE52A108BCA Q24203706-25C90A12-973E-4F27-A8BD-8C832B1FED02 Q24240074-86C5E385-8875-4441-9B53-FEF121C9C442 Q24240702-E0235F13-A4DB-42EC-92BB-6343C371DE2D Q24811196-E3A396B6-2E13-4F61-9D1C-4014817B20EC Q25256827-0EEB6B66-BE7A-4953-8EF9-D05106EFCBF5 Q26471040-2998ECA9-CA2C-4845-80CC-82A53A1EDFCC Q26853131-379EDF52-7009-4DE7-817B-69007912298C Q33419694-B78C9754-CA7C-4EA3-8F98-4101F93249E0 Q33648868-0B728964-3313-445E-87D2-69C33D18E396 Q33881536-B3FC9BFF-4DB3-484F-A46E-EB1A846D6DEB Q33920501-1C7BC5B3-D331-4F37-A042-376AAC293CBB Q33937152-EBB424F5-9C1F-43AB-A95A-8B1AB0CFAD15 Q34123608-3DA70EAC-4CAF-43B8-84DB-9574852B1900 Q34540179-83F473EC-E06E-4618-AABE-027CC7DEE02D Q35127300-3BEB43DC-B1AB-450A-B706-95A69A116EB6 Q35382696-2C8D74F8-29D8-4E06-BBD5-D3E80EA68CDF Q36322131-8C180B10-D974-4304-9BE2-01416C19527A Q36419843-1FCCD65E-9508-4DFF-B8F9-50E4E06D0A01 Q36445553-6CB1CE08-78CD-4530-9A3B-0EDC42D58633 Q36946801-BF3C3D4E-3AB8-4D0A-802B-365E5FF9B265 Q37290618-35A8E681-F33E-469B-AC1B-24A62BB093C3 Q37582861-9F99ECA9-C1D7-4562-AD10-28F3BDBF6FAA Q37586891-35AB092E-CBAA-4212-A85B-32201C88014B Q38058838-9D9F4D65-3170-40A8-B657-AFC470824779 Q38604949-A3A96F76-4794-4154-BE18-396304EF1036 Q38702381-7FF61D2B-6F5D-49F3-A0E4-7CC5CE5BEB2A Q38811618-7349A1BF-21E2-4370-A477-8D7BE61150F6 Q38945689-B2B37EB3-26CE-45AA-9ED2-A146CFB21A53 Q38969434-067C80F5-4785-42AA-ABB9-E6FBB21330C1 Q39655682-8715DF64-B677-4DBE-B9D1-13A88833682C Q40050175-E007D2D2-4E11-4DB5-B229-A13B8C26E0DE Q40166040-971AC417-921B-4DC4-A405-0DD1D2337193 Q40402380-F84FBC95-2403-4DE8-AD8F-74797B1EF61F Q40743239-D1BCED04-7622-48CE-B39C-5316ABF57B15 Q40959795-509C9C41-5DE5-4D94-B20A-F684EA7C376C Q42134462-3A08F857-03E3-487C-B455-988F2DF65D0B Q42260469-41C54224-7FED-4A73-9F14-AEC7B927AE75 Q42260782-655781A0-C8DE-489A-8648-68AC9D7C938F

P2860

Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model

http://www.wikidata.org/entity/Q37733544

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2004

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Anti-respiratory syncytial vir ...... siveness in a murine RSV model

@en

Anti-respiratory syncytial vir ...... iveness in a murine RSV model.

@nl

type

label

Anti-respiratory syncytial vir ...... siveness in a murine RSV model

@en

Anti-respiratory syncytial vir ...... iveness in a murine RSV model.

@nl

prefLabel

Anti-respiratory syncytial vir ...... siveness in a murine RSV model

@en

Anti-respiratory syncytial vir ...... iveness in a murine RSV model.

@nl

P1433

Q37733544-9DCF783A-0460-4B95-90A3-B163EDA471E3

P1476

Q37733544-A6EB3CEC-5634-4D4B-A1EB-2E9115C9D499

P2093

Q37733544-2C5C5FB3-61D7-4581-8688-1A8BF161A1B5

Q37733544-4E20C46D-C24C-44A8-8C20-426ADBEB459F

Q37733544-5A745457-DA61-4F6D-BD1B-30BB3C3BE38A

Q37733544-5B2766C1-32D0-465A-A925-D9351ED17C23

Q37733544-60DE3E4E-5A50-42FF-9A2E-3B88B301F535

Q37733544-95EF1F36-F642-49AC-A822-390A0BA73F01

Q37733544-A911449D-37E4-45B4-9DDD-8049CCB9223A

Q37733544-AE1EC23D-CE4F-4399-80DE-8F7E87C039AC

Q37733544-DEF7C0D0-C839-4625-89F7-75D3BF55796A

P2860

Q37733544-0093B1E7-C3E3-4D28-94AF-658007FC5766

Q37733544-036C43C3-2076-44F5-BCC1-47D5F1BC7436

Q37733544-03B5892C-B229-419C-A42B-DEE6FCFE8202

Q37733544-068B37B1-C1AB-426D-8C10-2BFA956942BB

Q37733544-11722940-6AF2-4EAA-8D98-0B45032DBA70

Q37733544-12F16AB1-C634-4293-968F-D791E5D36B28

Q37733544-1D49FCDB-09D1-4F59-9585-3A2F137B9146

Q37733544-1EF22574-B1DE-4FF4-B74E-9158CB5833E1

Q37733544-22E99286-6C1C-487B-B9EF-0ECE0527AA96

Q37733544-27E233D9-3BAE-46AC-9A75-E91A4B585360

P304

Q37733544-9514BAC6-A1F3-4DA0-B375-32E95CD0D3C7

P31

Q37733544-8BA265E0-7A15-4DB2-84F8-5F2FA6A18FBF

P356

Q37733544-424B3349-D306-40D5-ABAA-6E73E2B269BE

P407

Q37733544-5D7C5396-536E-466F-A635-BCABD9233A14

P433

Q37733544-5B87BC41-C037-42A2-8873-C0CE1929E7B2

P478

Q37733544-FB71C5C7-F68D-4F06-8A4F-851ADBD2B052

P50

Q37733544-B0D1B1D4-8B67-46EA-BE7F-ADC367D28ED0

P577

Q37733544-102CA395-A89C-452D-ABE6-14DF1FD3E229

P698

Q37733544-4DB296B9-C1CB-493F-87F2-7D7C1D278AA6

P921

Q37733544-E1CCEFA9-98D9-4AF7-9709-4B05CFD231D6

Q37733544-F7EBE241-44A9-4FB7-91F2-5B55A4CC0EE4

P932

Q37733544-640A9A28-C07C-48A1-8DC8-3B1486812CF5

P356

AAC.48.5.1811-1822.2004

P1433

Antimicrobial Agents and Chemotherapy

P1476

Anti-respiratory syncytial vir ...... siveness in a murine RSV model

@en

P2093

Ana María Gómez

http://www.w3.org/2001/XMLSchema#string

Ana María Ríos

http://www.w3.org/2001/XMLSchema#string

Hasan S Jafri

http://www.w3.org/2001/XMLSchema#string

Jeanine Hatfield

http://www.w3.org/2001/XMLSchema#string

Jesús Saavedra-Lozano

http://www.w3.org/2001/XMLSchema#string

Mónica Fonseca Aten

http://www.w3.org/2001/XMLSchema#string

Octavio Ramilo

http://www.w3.org/2001/XMLSchema#string

Payal Kapur

http://www.w3.org/2001/XMLSchema#string

Susana Chávez-Bueno

http://www.w3.org/2001/XMLSchema#string

P2860

RSV-induced immunopathology: dynamic interplay between the virus and host immune response.

2. Cytokines and chemokines.

Palivizumab for respiratory syncytial virus prophylaxis.

Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus.

Elevated cytokine and chemokine levels and prolonged pulmonary airflow resistance in a murine Mycoplasma pneumoniae pneumonia model: a microbiologic, histologic, immunologic, and respiratory plethysmographic profile.

Antibodies for the prevention and treatment of viral diseases.

Respiratory syncytial virus and influenza A infections in the hospitalized elderly.

Neutralizing anti-F glycoprotein and anti-substance P antibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection.

Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.

New approaches to respiratory infections in children. Bronchiolitis and croup.

P304

1811-1822

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.48.5.1811-1822.2004

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P50

Asuncion Mejias

P577

2004-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15105140

http://www.w3.org/2001/XMLSchema#string

P921

P932

400529

http://www.w3.org/2001/XMLSchema#string